

### **Remarks**

Claims 9 and 11-14 are pending in the present application after entry of this Amendment. Claims 1-8, 10, and 15-30 are canceled herein. Claim 9 has been amended in response to the restriction requirement as discussed below. Claim 11 has been amended to add reference to SEQ ID NO: 11. This amendment corrects for a typographical error and finds support in the specification as filed on page 8, line 20.

No new matter is added through the amendments presented herein. Applicants respectfully request reconsideration of the present application in view of the foregoing amendments and in view of the reasons that follow.

### **Restriction Requirement**

The Examiner has requested restriction under 35 U.S.C. 121 and 372 (PCT Rules 13.1-13.3) to one of the Groups (I-VII) as set forth in the pending Office Action. Applicants elect, without traverse, Group I (claims 1, 7, 9, 13, and 14 in part, and claims 2-4, 11, 12, and 22-29) drawn to anti-WISP-1 antibodies and a method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44, or RHAMM in mammalian cells, comprising exposing said mammalian cells to a WISP-1 antibody. Claims 1-4, 7, and 22-29 of Group I have been canceled without prejudice. Applicant reserves the right to pursue the subject matter presented in these claims at a later time.

Claim 9 has been amended to direct the claims to the invention of Group I.

### **Election of Species Requirement**

In response to the election of species requirement set forth in the pending Office Action as it pertains to claim 11, Applicants elect species f) amino acids encoded by the sequence of SEQ ID NO:3. As noted by the Examiner, claims 9 and 11-14 are generic claims. Each of these claims is readable on the elected species.

Applicant expressly reserves the right under 35 U.S.C. §121 to file one or more divisional applications directed to the non-elected subject matter, as well as any other matter disclosed in the present application which is not encompassed by the elected claims, during the pendency of the present application or an application claiming priority from this application.


If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is strongly encouraged to call the undersigned at the number indicated below.

Respectfully submitted,

GENENTECH, INC.

Date: May 29, 2007

By:



Traci H. Ropp

Reg. No. 44,307

Telephone No. (650) 467-0481